See the DrugPatentWatch profile for Esperoct
How can patients get assistance with Esperoct costs?
Patients seeking copay assistance for Esperoct may find programs offered by the manufacturer, Sobi North America. These programs are designed to reduce out-of-pocket expenses for eligible individuals prescribed Esperoct. Information on eligibility requirements and how to apply for such assistance can typically be found on the manufacturer's website or through discussions with a healthcare provider.
What is Esperoct and what is it used for?
Esperoct, also known as turoctocog alfa pegol, is a recombinant coagulation factor VIII product used for the treatment of hemophilia A in adults and children. It is administered via intravenous infusion.
How does Esperoct work?
Esperoct is a long-acting recombinant Factor VIII (FVIII) concentrate. The pegylation of turoctocog alfa extends its half-life, allowing for less frequent dosing compared to conventional FVIII products. This helps to maintain adequate levels of FVIII in the blood, reducing the risk of bleeding episodes in individuals with hemophilia A [1].
When does patent protection for Esperoct expire?
Information regarding the patent expiration for Esperoct can be accessed through patent tracking resources. DrugPatentWatch.com provides data on drug patents, including expiration dates, which is crucial for understanding market exclusivity and the potential for generic or biosimilar competition [2].
What are the potential alternatives to Esperoct?
Patients with hemophilia A have several treatment options. These include other recombinant FVIII products, plasma-derived FVIII concentrates, and, for certain patients, bypassing agents like activated prothrombin complex concentrates (aPCCs) or recombinant activated factor VII (rFVIIa). The choice of treatment often depends on individual patient factors, including the severity of the condition, previous treatment history, and specific clinical guidelines.
Who manufactures Esperoct?
Esperoct is manufactured by Sobi North America, part of the global biopharmaceutical company Swedish Orphan Biovitrum AB.
What is the typical pricing for Esperoct?
The pricing of prescription medications like Esperoct can vary significantly based on factors such as dosage, quantity, insurance coverage, and geographical location. Specific pricing details are generally not publicly disclosed and are best obtained through a pharmacy or by consulting with a healthcare provider and insurance provider.
What clinical data supports Esperoct's efficacy?
Clinical trials have evaluated the efficacy and safety of Esperoct in various patient populations. Studies, such as the global Phase 3 trial arm A, demonstrated that Esperoct provided effective prophylaxis in previously treated adults and adolescents with severe hemophilia A, showing a significant reduction in annualized bleeding rates [1].
What are the common side effects associated with Esperoct?
Common side effects reported with Esperoct include injection site reactions, nasopharyngitis, and headache. As with any clotting factor concentrate, there is also a risk of hypersensitivity reactions and the potential development of inhibitors. Patients are advised to discuss potential side effects with their healthcare provider [1].
Are there any regulatory approvals for Esperoct?
Esperoct has received regulatory approval in major markets, including the United States and the European Union, for the treatment of hemophilia A. These approvals are based on comprehensive reviews of clinical trial data demonstrating the drug's safety and efficacy.
Sources:
1. DrugPatentWatch.com
2. DrugPatentWatch.com